These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 24935992

  • 21. Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A.
    Li S, Naganawa M, Pracitto R, Najafzadeh S, Holden D, Henry S, Matuskey D, Emery PR, Cai Z, Ropchan J, Nabulsi N, Carson RE, Huang Y.
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1327-1338. PubMed ID: 33416954
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11 C]UCB-J positron emission tomography study.
    Finnema SJ, Toyonaga T, Detyniecki K, Chen MK, Dias M, Wang Q, Lin SF, Naganawa M, Gallezot JD, Lu Y, Nabulsi NB, Huang Y, Spencer DD, Carson RE.
    Epilepsia; 2020 Oct; 61(10):2183-2193. PubMed ID: 32944949
    [Abstract] [Full Text] [Related]

  • 26. Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem.
    Bertoglio D, Verhaeghe J, Wyffels L, Miranda A, Stroobants S, Mrzljak L, Dominguez C, Skinbjerg M, Bard J, Liu L, Munoz-Sanjuan I, Staelens S.
    J Nucl Med; 2022 Jun; 63(6):942-947. PubMed ID: 34531262
    [Abstract] [Full Text] [Related]

  • 27. First-in-Human Evaluation of 18F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2A.
    Naganawa M, Li S, Nabulsi N, Henry S, Zheng MQ, Pracitto R, Cai Z, Gao H, Kapinos M, Labaree D, Matuskey D, Huang Y, Carson RE.
    J Nucl Med; 2021 Apr; 62(4):561-567. PubMed ID: 32859701
    [Abstract] [Full Text] [Related]

  • 28. Preclinical PET Studies of [11C]UCB-J Binding in Minipig Brain.
    Thomsen MB, Schacht AC, Alstrup AKO, Jacobsen J, Lillethorup TP, Bærentzen SL, Noer O, Orlowski D, Elfving B, Müller HK, Brooks DJ, Landau AM.
    Mol Imaging Biol; 2020 Oct; 22(5):1290-1300. PubMed ID: 32514885
    [Abstract] [Full Text] [Related]

  • 29. Assessment of synaptic loss in mouse models of β-amyloid and tau pathology using [18F]UCB-H PET imaging.
    Vogler L, Ballweg A, Bohr B, Briel N, Wind K, Antons M, Kunze LH, Gnörich J, Lindner S, Gildehaus FJ, Baumann K, Bartenstein P, Boening G, Ziegler SI, Levin J, Zwergal A, Höglinger GU, Herms J, Brendel M.
    Neuroimage Clin; 2023 Oct; 39():103484. PubMed ID: 37541098
    [Abstract] [Full Text] [Related]

  • 30. Kinetics and 28-day test-retest repeatability and reproducibility of [11C]UCB-J PET brain imaging.
    Tuncel H, Boellaard R, Coomans EM, de Vries EF, Glaudemans AW, Feltes PK, García DV, Verfaillie SC, Wolters EE, Sweeney SP, Ryan JM, Ivarsson M, Lynch BA, Schober P, Scheltens P, Schuit RC, Windhorst AD, De Deyn PP, van Berckel BN, Golla SS.
    J Cereb Blood Flow Metab; 2021 Jun; 41(6):1338-1350. PubMed ID: 34013797
    [Abstract] [Full Text] [Related]

  • 31. Tracing synaptic loss in Alzheimer's brain with SV2A PET-tracer UCB-J.
    Kumar A, Scarpa M, Nordberg A.
    Alzheimers Dement; 2024 Apr; 20(4):2589-2605. PubMed ID: 38363009
    [Abstract] [Full Text] [Related]

  • 32. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M, Fuks B, Leclercq K, Matagne A.
    Eur J Pharmacol; 2011 Aug 16; 664(1-3):36-44. PubMed ID: 21575627
    [Abstract] [Full Text] [Related]

  • 33. Discovery and development of SV2A PET tracers: Potential for imaging synaptic density and clinical applications.
    Mercier J, Provins L, Valade A.
    Drug Discov Today Technol; 2017 Nov 16; 25():45-52. PubMed ID: 29233267
    [Abstract] [Full Text] [Related]

  • 34. In vivo imaging of synaptic density with [11C]UCB-J PET in two mouse models of neurodegenerative disease.
    Xiong M, Roshanbin S, Rokka J, Schlein E, Ingelsson M, Sehlin D, Eriksson J, Syvänen S.
    Neuroimage; 2021 Oct 01; 239():118302. PubMed ID: 34174391
    [Abstract] [Full Text] [Related]

  • 35. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
    Gillard M, Chatelain P, Fuks B.
    Eur J Pharmacol; 2006 Apr 24; 536(1-2):102-8. PubMed ID: 16556440
    [Abstract] [Full Text] [Related]

  • 36. Enabling Efficient Positron Emission Tomography (PET) Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) with a Robust and One-Step Radiosynthesis of a Highly Potent 18F-Labeled Ligand ([18F]UCB-H).
    Warnier C, Lemaire C, Becker G, Zaragoza G, Giacomelli F, Aerts J, Otabashi M, Bahri MA, Mercier J, Plenevaux A, Luxen A.
    J Med Chem; 2016 Oct 13; 59(19):8955-8966. PubMed ID: 27598384
    [Abstract] [Full Text] [Related]

  • 37. Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A.
    Naganawa M, Gallezot JD, Finnema SJ, Maguire RP, Mercier J, Nabulsi NB, Kervyn S, Henry S, Nicolas JM, Huang Y, Chen MK, Hannestad J, Klitgaard H, Stockis A, Carson RE.
    EJNMMI Res; 2022 Nov 08; 12(1):71. PubMed ID: 36346513
    [Abstract] [Full Text] [Related]

  • 38. Autoradiographic mapping of synaptic vesicle glycoprotein 2A in non-human primate and human brain.
    Varnäs K, Stepanov V, Halldin C.
    Synapse; 2020 Oct 08; 74(10):e22157. PubMed ID: 32259300
    [Abstract] [Full Text] [Related]

  • 39. Association of synaptic density and cognitive performance in temporal lobe epilepsy: Humans and animals PET imaging study with [18F]SynVesT-1.
    Xiao L, Xiang S, Chen C, Zhu H, Zhou M, Tang Y, Feng L, Hu S.
    Psychiatry Clin Neurosci; 2024 Aug 08; 78(8):456-467. PubMed ID: 38804583
    [Abstract] [Full Text] [Related]

  • 40. Synaptic Terminal Density Early in the Course of Schizophrenia: An In Vivo UCB-J Positron Emission Tomographic Imaging Study of SV2A.
    Onwordi EC, Whitehurst T, Shatalina E, Mansur A, Arumuham A, Osugo M, Marques TR, Jauhar S, Gupta S, Mehrotra R, Rabiner EA, Gunn RN, Natesan S, Howes OD.
    Biol Psychiatry; 2024 Apr 01; 95(7):639-646. PubMed ID: 37330164
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.